PGFC
CRSP icon

Peapack-Gladstone Financial Corp’s CRISPR Therapeutics CRSP Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Hold
6,988
– – ﹤0.01% 554
2026
Q1 		$332K Buy
6,988
+15
+0.2% +$791 ﹤0.01% 564
2025
Q4 		$366K Hold
6,973
– – ﹤0.01% 548
2025
Q3 		$452K Hold
6,973
– – 0.01% 521
2025
Q2 		$339K Buy
6,973
+200
+3% +$7.74K ﹤0.01% 536
2025
Q1 		$230K Hold
6,773
– – ﹤0.01% 615
2024
Q4 		$266K Hold
6,773
– – ﹤0.01% 590
2024
Q3 		$318K Buy
6,773
+130
+2% +$6.6K ﹤0.01% 561
2024
Q2 		$359K Hold
6,643
– – 0.01% 535
2024
Q1 		$453K Buy
6,643
+2,053
+45% +$147K 0.01% 499
2023
Q4 		$288K Hold
4,590
– – ﹤0.01% 577
2023
Q3 		$208K Hold
4,590
– – ﹤0.01% 630
2023
Q2 		$258K Buy
+4,590
New +$260K ﹤0.01% 595

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Peapack-Gladstone Financial Corp's CRSP Position: Q2 2026 in Review

Peapack-Gladstone Financial Corp held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 6,988 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #554.

Peapack-Gladstone Financial Corp first reported a position in CRSP in Q2 2023 and has held it in 13 quarters since. The position peaked at $453K in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Peapack-Gladstone Financial Corp held 6,988 shares of CRISPR Therapeutics worth $381K as of Q2 2026.
  • Peapack-Gladstone Financial Corp left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Peapack-Gladstone Financial Corp's portfolio in Q2 2026, its #554 holding.
  • Peapack-Gladstone Financial Corp first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Peapack-Gladstone Financial Corp's CRISPR Therapeutics position peaked at $453K in Q1 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2026, filed 14 Aug 2026.